Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 916 to 930 of 1561 results for do not do recommendations

  1. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    Recommendation ID NG150/1 Question What is the effectiveness, cost effectiveness and acceptability of the whole family approach to...

  2. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  3. Our research work

    Our science policy and research programme team produces high-quality, impactful research.

  4. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  5. Recommendation 1 Research studies and trials. Who should take action? Research councils, commissioners and funders.

    Recommendation ID PH47/1 Question Recommendation 1 Research studies and trials. Who should take action? Research councils,...

  6. Recommendation 4 Weight management programmes. Who should take action? Research councils, commissioners and funders. Researchers and investigators.

    Recommendation ID PH47/4 Question Recommendation 4 Weight management programmes. Who should take action? Research councils,...

  7. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

  8. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  9. Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

  10. Midcarpal hemiarthroplasty for wrist arthritis (HTG529)

    Evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. This involves using a metal implant to create an artificial wrist joint, to relieve pain and maintain movement.

  11. Tocilizumab for the treatment of rheumatoid arthritis (TA247)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.

  12. Gastro-oesophageal reflux in children and young people (QS112)

    This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

  13. Devices for remote monitoring of Parkinson's disease (HTG657)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.

  14. Endoscopic full thickness removal of non-lifting colonic polyps (HTG439)

    Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.

  15. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.